Avelumab

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Avelumab (Bavencio) is a fully human anti-PD-L1 monoclonal antibody approved internationally for Merkel cell carcinoma and urothelial carcinoma maintenance therapy, though it is not currently registered in Denmark. The TxGNN model predicts it may be effective for HHV-8-related tumours (including Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman disease), with a prediction confidence of 99.97%. At present, no dedicated clinical trials or publications directly investigate this drug–disease combination, though the mechanistic rationale is substantiated by class-level evidence from the related checkpoint inhibitor pembrolizumab.

Quick Overview

Item	Content
Original Indication	Merkel cell carcinoma; urothelial carcinoma maintenance — globally approved (EMA/FDA); not registered in Denmark
Predicted New Indication	HHV-8-Related Tumour (Kaposi’s sarcoma, Primary Effusion Lymphoma, Castleman Disease)
TxGNN Prediction Score	99.97%
Evidence Level	L4
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Avelumab is a fully human IgG1 monoclonal antibody that blocks the interaction between PD-L1 and its receptors PD-1 and CD80, thereby restoring cytotoxic CD8+ T cell and NK cell activity against tumour cells. Critically, unlike other checkpoint inhibitors, Avelumab’s IgG1 Fc region retains antibody-dependent cell-mediated cytotoxicity (ADCC) activity — enabling direct tumour cell killing through NK cell engagement, a second mechanism of action beyond checkpoint blockade alone.

Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman disease. HHV-8-infected malignant cells are known to upregulate PD-L1 expression as an immune evasion strategy, suppressing both anti-viral and anti-tumour immune surveillance by CD8+ T cells and NK cells. Blocking PD-L1 with Avelumab could therefore restore immune-mediated killing of HHV-8-harbouring cells through two complementary pathways — checkpoint disinhibition and direct ADCC — potentially offering a dual advantage over anti-PD-1 agents in this setting.

Class-level biological plausibility is supported by the fact that pembrolizumab (an anti-PD-1 antibody) has entered Phase 2 clinical evaluation in Kaposi’s sarcoma (NCT02494960). This precedent indicates that the broader immune checkpoint inhibitor class is considered mechanistically sound for HHV-8-associated malignancies by the clinical research community. TxGNN’s high prediction score of 99.97% reflects this mechanistic alignment as captured in the knowledge graph, even in the absence of Avelumab-specific trial data.

Clinical Trial Evidence

Currently no related clinical trials registered specifically for Avelumab in HHV-8-related tumours.

Class-level note: The related anti-PD-1 agent pembrolizumab has an ongoing Phase 2 trial in Kaposi’s sarcoma — NCT02494960 — providing indirect evidence that immune checkpoint inhibition is biologically feasible in this disease context.

Literature Evidence

Currently no related literature available for Avelumab specifically in HHV-8-related tumours.

Cytotoxicity

Avelumab is an oncology immunotherapy agent (anti-PD-L1 monoclonal antibody). This section applies.

Item	Content
Cytotoxicity Classification	Immunotherapy — immune checkpoint inhibitor (anti-PD-L1 IgG1 monoclonal antibody with ADCC activity); not a conventional cytotoxic agent
Myelosuppression Risk	Low for direct myelosuppression; immune-mediated haematological events (e.g. immune thrombocytopenia, haemolytic anaemia) are possible irAEs
Emetogenicity Classification	Minimal
Monitoring Items	Full blood count (CBC with differential), liver function tests (ALT, AST, bilirubin), renal function (creatinine), thyroid function (TSH, free T4), fasting blood glucose, cortisol (adrenal function); infusion reaction monitoring during and after administration
Handling Protection	Standard monoclonal antibody handling precautions apply; dedicated cytotoxic drug handling regulations are not required

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Important clinical note: As a checkpoint inhibitor, Avelumab carries class-specific immune-related adverse events (irAEs) that require active monitoring and management. These include, but are not limited to: immune-mediated pneumonitis, colitis, hepatitis, nephritis, endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus), and infusion-related reactions. Practitioners should follow current immunotherapy toxicity management guidelines (e.g. ESMO/ASCO irAE guidelines). The Bavencio SmPC approved by EMA provides the authoritative full safety profile.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for Avelumab specifically in HHV-8-related tumours is currently at the preclinical/mechanistic level only (L4), with no registered clinical trials and no published literature directly investigating this drug–disease combination. The mechanistic basis is scientifically sound — HHV-8-driven PD-L1 upregulation is well described, and class-level evidence from pembrolizumab in Kaposi’s sarcoma supports the plausibility of checkpoint inhibition in this setting — but drug-specific clinical validation is entirely absent.

To proceed, the following is needed:

Systematic review of the existing pembrolizumab Kaposi’s sarcoma trial (NCT02494960) results to assess class-level transferability to Avelumab
Translational or preclinical data specifically addressing whether Avelumab’s ADCC mechanism confers additional benefit over anti-PD-1 agents in HHV-8-associated malignancies
PD-L1 expression prevalence data across the spectrum of HHV-8-related tumour subtypes (Kaposi’s sarcoma, PEL, Castleman disease), including assessment in immunocompromised subpopulations (HIV-positive patients)
Full SmPC review and safety gap remediation: the current Evidence Pack is missing key safety data (TFDA/EMA warnings, contraindications, drug–drug interactions) which are classified as blocking for formal safety pre-screening (DG001)
Danish epidemiological feasibility assessment: HHV-8-related malignancies are uncommon in Denmark; patient population sizing is needed to evaluate clinical and health-economic viability
Registration pathway analysis: Avelumab is not currently marketed in Denmark; any clinical use would require a named patient programme, compassionate use authorisation, or a prospective clinical trial
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.